Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update on its activities for the quarter ended 30 September 2018 and an update on business progress.
View IBX Appendix 4C — September 2018 Quarterly Update
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance